Takeda and Ovid Therapeutics with soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, holds promise for transformative therapy marking a milestone in advancing treatment options for individuals with refractory epilepsies associated with Dravet syndrome and Lennox-Gastaut syndrome.
Soticlestat by modulating cholesterol homeostasis and glutamatergic pathways, presents a pioneering approach to reducing seizure susceptibility and improving seizure control.
Current treatments for epilepsy predominantly address symptomatic seizure control, frequently falling short in targeting fundamental disease mechanisms, thus leaving approximate...
